Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 5
Submit an article Journal homepage
280
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Generation of high-avidity, WT1-reactive CD8+ cytotoxic T cell clones with anti-leukemic activity by streptamer technology

Antje TungerInstitute of Immunology, Medical Faculty, TU Dresden, Dresden, Germany;
,
Rebekka WehnerInstitute of Immunology, Medical Faculty, TU Dresden, Dresden, Germany; ;National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany;
,
Malte von BoninNational Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;Department of Medicine I, University Hospital of Dresden, Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany;
,
Denise KühnCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;
,
Falk HeidenreichDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany;
,
Sarah MatkoInstitute of Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany;
,
Magdalena NauerthInstitute for Medical Microbiology, Immunology and Hygiene, TU Munich, Munich, Germany;
,
Elke Rücker-BraunDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany;
,
Sevina DietzCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;
,
Cornelia S. LinkDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;
,
Anne EugsterCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;
,
Marcus OdendahlInstitute of Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany;
,
Dirk H. BuschInstitute for Medical Microbiology, Immunology and Hygiene, TU Munich, Munich, Germany;
,
Torsten TonnGerman Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany; ;Institute of Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany;
,
Ezio BonifacioCenter for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;
,
Lothar GermerothJuno Therapeutics GmbH, Göttingen, Germany;
,
Johannes ScheteligDepartment of Medicine I, University Hospital of Dresden, Dresden, Germany;
,
Michael P. BachmannNational Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany; ;Department of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz Center Dresden-Rossendorf, Dresden, Germany
,
Martin BornhäuserNational Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;Department of Medicine I, University Hospital of Dresden, Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany;
&
Marc SchmitzInstitute of Immunology, Medical Faculty, TU Dresden, Dresden, Germany; ;National Center for Tumor Diseases, University Hospital Carl Gustav Carus, TU Dresden, Germany; ;German Cancer Consortium (DKTK), Dresden, Germany; ;German Cancer Research Center (DKFZ), Heidelberg, Germany; ;Center for Regenerative Therapies Dresden (CRTD), Medical Faculty, TU Dresden, Dresden, Germany; Correspondence[email protected]
 show all
Pages 1246-1249 | Received 13 Jul 2016, Accepted 31 Aug 2016, Published online: 16 Nov 2016

References

  • Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115:1850–1857.
  • Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–4383.
  • Rambaldi A, Biagi E, Bonini C, et al. Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia. 2015;29:1–10.
  • Anguille S, Van Tendeloo V, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012;26:2186–2196.
  • Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–5337.
  • Gao L, Bellantuono I, Elsässer A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198–2203.
  • Doubrovina ES, Doubrovin MM, Lee S, et al. In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity. Clin Cancer Res. 2004;10:7207–7219.
  • Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist. 2012;17:250–259.
  • Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013;5:174ra27. doi: 10.1126/scitranslmed.3004916.
  • Knabel M, Franz TJ, Schiemann M, et al. Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med. 2002;8:631–637.
  • Schmitt A, Tonn T, Busch DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion. 2011;51:591–599.
  • Skowera A, Ellis RJ, Varela-Calviño R, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest. 2008;118:3390–3402.
  • Nauerth M, Weißbrich B, Knall R, et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med. 2013;5:192ra87. doi: 10.1126/scitranslmed.3005958.
  • Nauerth M, Weissbrich B, Busch DH. The clinical potential for koff-rate measurement in adoptive immunotherapy. Expert Rev Clin Immunol. 2013;9:1151–1153.
  • Jaigirdar A, Rosenberg SA, Parkhurst M. A high-avidity WT1-reactive T-cell receptor mediates recognition of peptide and processed antigen but not naturally occurring WT1-positive tumor cells. J Immunother. 2016;39:105–116.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.